^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aprutumab ixadotin (BAY1187982)

    i
    Other names: BAY1187982, FGFR2-ADC, BAY 1187982
    Associations

    News

    Trials
    Company:
    Bayer
    Drug class:
    Microtubule inhibitor, FGFR2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4years
    First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. (PubMed, Target Oncol)
    Aprutumab ixadotin was poorly tolerated, with an MTD found to be below the therapeutic threshold estimated preclinically; therefore, the trial was terminated early. CLINICALTRIALS.
    Clinical • P1 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    aprutumab ixadotin (BAY1187982)